The Effective Targeting of KRASG12C Elusiveness

被引：1

作者：

Elez, Filiation Elena ^{[1
]}

Tabernero, Josep ^{[1
]}

机构：

[1] Univ Autonoma Barcelona UAB, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

来源：

CANCER CELL | 2020年 / 38卷 / 06期

关键词：

MECHANISM; KRAS;

D O I：

10.1016/j.ccell.2020.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.

引用

页码：785 / 787

页数：3

共 50 条

[31] Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, Mei
Xiong, Yuan
Safaee, Nozhat
Nowak, Radosaw P.
Donovan, Katherine A.
Yuan, Christine J.
Nabet, Behnam
Gero, Thomas W.
Feru, Frederic
Li, Lianbo
Gondi, Sudershan
Ombelets, Lincoln J.
Quan, Chunshan
Janne, Pasi A.
Kostic, Milka
Scott, David A.
Westover, Kenneth D.
Fischer, Eric S.
Gray, Nathanael S.
CELL CHEMICAL BIOLOGY, 2020, 27 (01): : 19 - +
[32] Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, Marcelo V.
Araujo, Haniel A.
Lamberti, Giuseppe
Cooper, Alissa J.
Akhave, Neal S.
Zhou, Teng
Delasos, Lukas
Hicks, J. Kevin
Aldea, Mihaela
Minuti, Gabriele
Hines, Jacobi
Aredo, Jacqueline V.
Dennis, Michael J.
Chakrabarti, Turja
Scott, Susan C.
Bironzo, Paolo
Scheffler, Matthias
Christopoulos, Petros
Stenzinger, Albrecht
Riess, Jonathan W.
Kim, So Yeon
Goldberg, Sarah B.
Li, Mingjia
Wang, Qi
Qing, Yun
Ni, Ying
Do, Minh Truong
Lee, Richard
Ricciuti, Biagio
Alessi, Joao Victor
Wang, Jing
Resuli, Blerina
Landi, Lorenza
Tseng, Shu-Chi
Nishino, Mizuki
Digumarthy, Subba R.
Rinsurongkawong, Waree
Rinsurongkawong, Vadeerat
Vaporciyan, Ara A.
Blumenschein, George R., Jr.
Zhang, Jianjun
Owen, Dwight H.
Blakely, Collin M.
Mountzios, Giannis
Shu, Catherine A.
Bestvina, Christine M.
Garassino, Marina Chiara
Marrone, Kristen A.
Gray, Jhanelle E.
Patel, Sandip Pravin
CANCER DISCOVERY, 2023, 13 (07) : 1556 - 1571
[33] Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
Wijeratne, Aruna
Xiao, Junpeng
Reutter, Christopher
Furness, Kelly W.
Leon, Rebecca
Zia-Ebrahimi, Mohammad
Cavitt, Rachel N.
Strelow, John M.
Van Horn, Robert D.
Peng, Sheng-Bin
Barda, David A.
Engler, Thomas A.
Chalmers, Michael J.
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (06): : 557 - 562
[34] Adaptive resistance mechanisms to KRASG12C specific inhibitors
Solanki, Hitendra Singh
Fang, Bin
Welsh, Eric A.
Tan, Aik C.
Kinose, Fumi
Rix, Uwe
Haura, Eric B.
CANCER RESEARCH, 2020, 80 (16)
[35] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, David S.
Fakih, Marwan G.
Strickler, John H.
Desai, Jayesh
Durm, Gregory A.
Shapiro, Geoffrey I.
Falchook, Gerald S.
Price, Timothy J.
Sacher, Adrian
Denlinger, Crystal S.
Bang, Yung-Jue
Dy, Grace K.
Krauss, John C.
Kuboki, Yasutoshi
Kuo, James C.
Coveler, Andrew L.
Park, Keunchil
Kim, Tae Won
Barlesi, Fabrice
Munster, Pamela N.
Ramalingam, Suresh S.
Burns, Timothy F.
Meric-Bernstam, Funda
Henary, Haby
Ngang, Jude
Ngarmchamnanrith, Gataree
Kim, June
Houk, Brett E.
Canon, Jude
Lipford, J. Russell
Friberg, Gregory
Lito, Piro
Govindan, Ramaswamy
Li, Bob T.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13): : 1207 - 1217
[36] BPI-421286: A highly potent small molecule inhibitor targeting KRASG12C mutation
Zhu, Xiaoguan
Lu, Yuan
Guo, Jing
Yan, Dan
Li, Boyan
Chen, Xiaoping
Chen, Haibo
Lan, Hong
Wu, Hao
Ding, Lieming
Wang, Jiabing
CANCER RESEARCH, 2022, 82 (12)
[37] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jimenez, Javier
Espinar, Javier Baena
de Cabo, Helena Bote
Berjaga, Maria Zurera
Esteban-Villarrubia, Jorge
Fraile, Jon Zugazagoitia
Paz-Ares, Luis
DRUGS, 2024, 84 (05) : 527 - 548
[38] Combination of KRASG12C and FGFR1 inhibitors as a resistance-overcoming therapeutic strategy for maximizing therapeutic impact of KRASG12C inhibitors
Santos, Alba
Plaza, Patricia
Jimenez, Marta
Gomez-Sanchez, David
Paz-Ares, Luis
Ferrer, Irene
CANCER RESEARCH, 2024, 84 (06)
[39] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with KRASG12C inhibitors in multiple KRASG12C models
Jameson, Nathan M.
Kim, Gabriel
Lee, Catherine
Skrable, Blake
Shea, Alexandra
Abed, Monah
Harismendy, Olivier
Ma, Jianhui
Kim, Doris
Lackner, Mark R.
CANCER RESEARCH, 2024, 84 (06)
[40] Sotorasib shows clinical benefits in KRASG12C colorectal cancer
Di Lellis, Maddalena Angela
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (05):

← 1 2 3 4 5 →